Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Archives of Psychiatry and Clinical Neuroscience

18.11.2023 | Original Paper

Changes in neuroactive steroids, neurotrophins and immunological biomarkers after monotherapy 8-week rTMS treatment and their relationship with neurocognitive functions in depression

verfasst von: Muhammed Emin Boylu, Şenol Turan, Eray Metin Güler, Fatma Betül Boylu, Özge Kılıç, Abdurrahim Koçyiğit, İsmet Kırpınar

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience

Einloggen, um Zugang zu erhalten

Abstract

Repetitive transcranial magnetic stimulation (rTMS) has proven effective in the treatment of major depression. The underlying mechanisms of action are still poorly understood. We aimed to evaluate the changes in the levels of neuroactive steroids, neurotrophins and immunological biomarkers before and after rTMS treatment and assess the relationship of this change between clinical response and cognitive functions after monotherapy rTMS treatment. Twenty-three patients with major depressive disorder (MDD) and 25 matched healthy controls were included in the study. The Hamilton Depression Rating Scale (HDRS), Trail Making Test A and B forms and Digit Span Test were administered. Biomarkers (BDNF, TNF-α, IL-1ß, NAS) were run in the peripheral blood at the end of the first month that rTMS was administered daily and at the end of the 2nd month when that rTMS was administered once a week. Appropriate conditions were provided so that the relevant biomarkers were not affected by the biorhythm. After rTMS monotherapy, an increase in BDNF and allopregnanolone, a decrease in TNF-α, IL-1ß, DHEA, and DHEA-S levels was found to be statistically significant. The scores on cognitive tests increased with the treatment. Positive significant correlations was found between BDNF levels and cognitive tests at the end of the first and second months. Our findings suggest that the effects of rTMS treatment may be related to the neuroendocrine, neurotrophin, and immunological mechanisms. rTMS treatment is found to have positive effects on cognitive functions in the short term.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
George, M.S., et al., Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport: An International Journal for the Rapid Communication of Research in Neuroscience, 1995.
2.
Brunoni AR et al (2015) BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: a systematic review and meta-analysis. World J Biol Psychiatry 16(2):114–122PubMedCrossRef
3.
Padberg F et al (2002) Plasma concentrations of neuroactive steroids before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Neuropsychopharmacology 27(5):874–878PubMedCrossRef
4.
Kendler KS, Thornton LM, Gardner CO (2000) Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the “kindling” hypothesis. Am J Psychiatry 157(8):1243–1251PubMedCrossRef
5.
Monroe SM, Harkness KL (2005) Life stress, the" kindling" hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev 112(2):417PubMedCrossRef
6.
van Broekhoven F, Verkes RJ (2003) Neurosteroids in depression: a review. Psychopharmacology 165(2):97–110PubMedCrossRef
7.
Romeo E et al (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 155(7):910–913PubMedCrossRef
8.
Uzunova V et al (2004) Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur J Pharmacol 486(1):31–34PubMedCrossRef
9.
Longone P et al (2008) The complex roles of neurosteroids in depression and anxiety disorders. Neurochem Int 52(4–5):596–601PubMedCrossRef
10.
Naert G et al (2007) Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology 32(8–10):1062–1078PubMedCrossRef
11.
Martin J et al (2019) Weak correlations between serum and cerebrospinal fluid levels of estradiol, progesterone and testosterone in males. BMC Neurosci 20:1–6CrossRef
12.
Schulz K, Korz V (2010) Hippocampal testosterone relates to reference memory performance and synaptic plasticity in male rats. Front Behav Neurosci 4:187PubMedPubMedCentralCrossRef
13.
Russo-Neustadt A, Chen M (2005) Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 11(12):1495–1510PubMedCrossRef
14.
Egan MF et al (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257–269PubMedCrossRef
15.
Guilloux J-P et al (2012) Molecular evidence for BDNF-and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 17(11):1130–1142PubMedCrossRef
16.
Dwivedi Y et al (2003) Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60(8):804–815PubMedCrossRef
17.
Zunszain, P.A., N. Hepgul, and C.M. Pariante, Inflammation and depression. Behavioral neurobiology of depression and its treatment, 2013: p. 135–151.
18.
Zhao X et al (2019) Repetitive transcranial magnetic stimulation increases serum brain-derived neurotrophic factor and decreases interleukin-1β and tumor necrosis factor-α in elderly patients with refractory depression. J Int Med Res 47(5):1848–1855PubMedPubMedCentralCrossRef
19.
Yukimasa T et al (2006) High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 39(02):52–59PubMedCrossRef
20.
Zanardini R et al (2006) Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 91(1):83–86PubMedCrossRef
21.
Lang UE et al (2008) Acute prefrontal cortex transcranial magnetic stimulation in healthy volunteers: no effects on brain-derived neurotrophic factor (BDNF) concentrations in serum. J Affect Disord 107(1–3):255–258PubMedCrossRef
22.
23.
Akdemir A et al (1996) Hamilton depresyon derecelendirme ölçeği (HDDÖ)’nin geçerliliği-güvenirliliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 4(4):251–259
24.
Lezak M Neuropsychological Assessment 3rd Edition New York: Oxford University Press.[Google Scholar]. 1995.
25.
Bosgelmez S et al (2015) Reliability and validity of the Turkish version of cognitive assessment interview (CAI-TR). Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25(4):365–380CrossRef
26.
Benton AL (1945) A visual retention test for clinical use. Arch Neurol Psychiatry 54(3):212–216PubMedCrossRef
27.
Küçükdeveci AA et al (2013) The reliability and validity of the World Health Organization Disability Assessment Schedule (WHODAS-II) in stroke. Disabil Rehabil 35(3):214–220PubMedCrossRef
28.
Johnson KA et al (2013) Prefrontal rTMS for treating depression: location and intensity results from the OPT-TMS multi-site clinical trial. Brain Stimul 6(2):108–117PubMedCrossRef
29.
O’Reardon JP et al (2007) Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiat 62(11):1208–1216PubMedCrossRef
30.
George MS et al (2010) Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 67(5):507–516PubMedCrossRef
31.
Wang H-N et al (2017) Clustered repetitive transcranial magnetic stimulation for the prevention of depressive relapse/recurrence: a randomized controlled trial. Transl Psychiatry 7(12):1–9CrossRef
32.
Demiroz D et al. Neurotrophic Factor levels and cognitive functions before and after the repetitive transcranial magnetic stimulation in treatment resistant depression. Journal of the College of Physicians and Surgeons--pakistan: JCPSP, 2022. 32(3): p. 335–339.
33.
Uzunova V et al (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci 95(6):3239–3244PubMedPubMedCentralCrossRef
34.
Ströhle A et al (1999) Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiat 45(3):274–277PubMedCrossRef
35.
Sripada RK et al (2013) Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biol Psychiat 73(11):1045–1053PubMedCrossRef
36.
Maayan R et al (2000) Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol Psychiat 48(7):693–701PubMedCrossRef
37.
Wolkowitz OM et al (1999) Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 156(4):646–649PubMedCrossRef
38.
Maurice T, Roman FJ, Privat A (1996) Modulation by neurosteroids of the in vivo (+)-[3H] SKF-10,047 binding to σ1 receptors in the mouse forebrain. J Neurosci Res 46(6):734–743PubMedCrossRef
39.
Morsink LF et al (2007) Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC study. Psychoneuroendocrinology 32(8–10):874–883PubMedCrossRef
40.
Turan Ş et al (2014) Effects of electroconvulsive therapy on plasma levels of neuroactive steroids in inpatients with major depression. Int J Psychiatry Clin Pract 18(4):261–264PubMedCrossRef
41.
Schüle C et al (2003) Influence of sleep deprivation on neuroactive steroids in major depression. Neuropsychopharmacology 28(3):577–581PubMedCrossRef
42.
Schüle C, Nothdurfter C, Rupprecht R (2014) The role of allopregnanolone in depression and anxiety. Prog Neurobiol 113:79–87PubMedCrossRef
43.
Baghai TC et al (2005) Plasma concentrations of neuroactive steroids before and after electroconvulsive therapy in major depression. Neuropsychopharmacology 30(6):1181–1186PubMedCrossRef
44.
See RE et al (2021) Assessment of multiple salivary biomarkers during repetitive transcranial magnetic stimulation (rTMS) treatment for major depression. Psychiatry Res 302:114053PubMedCrossRef
45.
Barrett-Connor E et al (1999) Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 47(6):685–691PubMedCrossRef
46.
Schweiger U et al (1999) Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med 61(3):292–296PubMedCrossRef
47.
Shores MM et al (2005) Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry 66(1):10897CrossRef
48.
Perry PJ et al (2002) Testosterone therapy in late-life major depression in males. J Clin Psychiatry 63(12):20810CrossRef
49.
Seidman SN, Spatz E, Roose SP (2001) Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry 62(6):20806CrossRef
50.
Baischer W et al (1995) Hypothalamic-pituitary-gonadal axis in depressed premenopausal women: elevated blood testosterone concentrations compared to normal controls. Psychoneuroendocrinology 20(5):553–559PubMedCrossRef
51.
Weber B et al (2000) Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 25(8):765–771PubMedCrossRef
52.
Maehata K et al. (2020) Hippocampal 7α-hydroxylated neurosteroids are raised by training and bolster remote spatial memory with increase of the spine densities. Iscience 23(10).
53.
Chen C-Y et al. (2018) Gender differences in the relationships among neurosteroid serum levels, cognitive function, and quality of life. Neuropsychiatric Disease and Treatment: 2389–2399.
54.
55.
Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11(8):1169–1180PubMedCrossRef
56.
Molendijk M et al (2014) Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N= 9484). Mol Psychiatry 19(7):791–800PubMedCrossRef
57.
Liu JJ et al (2020) Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol Psychiatry 25(2):339–350PubMedCrossRef
58.
Hannestad J, DellaGioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36(12):2452–2459PubMedPubMedCentralCrossRef
59.
Dahl J et al (2014) The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 45:77–86PubMedCrossRef
60.
Perrin AJ, Pariante CM (2020) Endocrine and immune effects of non-convulsive neurostimulation in depression: a systematic review. Brain Behav Immun 87:910–920PubMedCrossRef
61.
Kim TD et al (2019) Cognitive enhancement in neurological and psychiatric disorders using transcranial magnetic stimulation (TMS): a review of modalities, potential mechanisms and future implications. Exp Neurobiol 28(1):1PubMedPubMedCentralCrossRef
62.
Vanderhasselt M-A et al (2006) The influence of rTMS over the left dorsolateral prefrontal cortex on Stroop task performance. Exp Brain Res 169(2):279–282PubMedCrossRef
63.
Martis B et al (2003) Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. Clin Neurophysiol 114(6):1125–1132PubMedCrossRef
64.
Myczkowski ML et al (2012) Effects of repetitive transcranial magnetic stimulation on clinical, social, and cognitive performance in postpartum depression. Neuropsychiatr Dis Treat 8:491PubMedPubMedCentralCrossRef
65.
Bridge DJ, Cohen NJ, Voss JL (2017) Distinct hippocampal versus frontoparietal network contributions to retrieval and memory-guided exploration. J Cogn Neurosci 29(8):1324–1338PubMedPubMedCentralCrossRef
66.
Sözeri-Varma G et al (2012) Relationship between serum BDNF levels and cognitive functions, cortisol levels in depressive disorder? Psychiatry Behav Sci 2(2):58–65
67.
Shimada H et al (2014) Depressive symptoms and cognitive performance in older adults. J Psychiatr Res 57:149–156PubMedCrossRef
Metadaten
Titel
Changes in neuroactive steroids, neurotrophins and immunological biomarkers after monotherapy 8-week rTMS treatment and their relationship with neurocognitive functions in depression
verfasst von
Muhammed Emin Boylu
Şenol Turan
Eray Metin Güler
Fatma Betül Boylu
Özge Kılıç
Abdurrahim Koçyiğit
İsmet Kırpınar
Publikationsdatum
18.11.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-023-01704-9

Neu im Fachgebiet Psychiatrie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise